Skip to main content

13-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Sustained reduction in disability progression with ocrelizumab in patients with primary progressive MS

Jerry Wolinsky discusses findings from the open-label extension phase of the phase III ORATORIO trial highlighting the benefits of early ocrelizumab treatment on disability progression in patients with primary progressive multiple sclerosis (10:24).

Funding for independent interviews at ECTRIMS 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.